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Although aberrant DNA methylation within imprinted domains has been reported in a variety of neoplastic diseases,
it remains largely uncharacterized in the context of carcinogenesis. In this study, we induced T-cell lymphoma in mice
by employing a breeding scheme involving mouse strains, LSL-KrasG12D and MMTV-Cre. We then systematically surveyed
imprinted domains for DNA methylation changes during tumor progression using combined bisulfite restriction
analysis and NGS-based bisulfite sequencing. We detected hyper- or hypo-methylation at the imprinting control
regions (ICRs) of the Dlk1, Peg10, Peg3, Grb10, and Gnas domains. These DNA methylation changes at ICRs were more
prevalent and consistent than those observed at the promoter regions of well-known tumor suppressors, such as Mgmt,
Fhit, and Mlh1. Thus, the changes observed at these imprinted domains are the outcome of isolated incidents affecting
DNA methylation settings. Within imprinted domains, DNA methylation changes tend to be restricted to ICRs as nearby
somatic differentially methylated regions and promoter regions experience no change. Furthermore, detailed analyses
revealed that small cis-regulatory elements within ICRs tend to be resistant to DNA methylation changes, suggesting
potential protection by unknown trans-factors. Overall, this study demonstrates that DNA methylation changes at ICRs
are dynamic during carcinogenesis and advocates that detection of aberrant DNA methylation at ICRs may serve as a
biomarker to enhance diagnostic procedures.
Introduction
DNA methylation at imprinting control regions (ICRs)
ensures proper dosage of imprinted genes by restricting their
expression from only one allele based upon parental origin.1 This
strict gene dosage control makes sense given the fact that
imprinted genes have critical roles in controlling fetal growth
rates, brain functions and energy regulations.1,2 The biochemical
functions of many imprinted gene products are also in accor-
dance with these roles, as they tend to be clustered in signaling
pathways responsible for either cell growth or death.3,4,5 Conse-
quently, perturbations to the epigenetic modifications that regu-
late imprinted gene dosage have been implicated as factors
contributing to neoplastic transformation of tumor cells.6,7
Among the approximate 100 imprinted genes identified thus far,
the following genes are frequently associated with cancer: Insulin-
Like Growth Factor 2 (Igf2), Igf2 Receptor (Igf2r), stimulatory
GTPase a (Gnas), Delta-Like 1 Homolog (Dlk1), Paternally
Expressed Gene 10 (Peg10), Paternally Expressed Gene 3 (Peg3),
Pleiomorphic Adenoma Gene-Like 1 (Plagl1/Zac1), Growth Factor
Receptor-Bound Protein 10 (Grb10), Ubiquitin Protein Ligase E3A
(Ube3A), andMesoderm-Specific Transcript (Mest).8
Imprinting control regions (ICRs) are the key cis-regulatory
elements that dictate the allele-specific expression patterns for
entire imprinted domains.1 ICRs and their associated allele-spe-
cific DNA methylation patterns are critical for establishing and
maintaining genomic imprinting.9 When an ICR is hyper- or
hypo-methylated, it cannot properly control expression of the
multiple mRNAs in the domain by either activating ncRNA in
cis or interacting with proteins that insulate promoters from distal
enhancer elements.10 Given the role DNA methylation plays in
the proper function of ICRs, it is reasonable to predict that aber-
rant DNA methylation of ICRs could disrupt the imprinting of
entire domains, which could then contribute to malignant trans-
formation. Indeed, both DNA methylation and genomic
imprinting are challenged in cancer.11,12 Therefore, within
imprinted domains, ICRs may be particularly vulnerable to aber-
rant DNA methylation during tumor progression. However, the
timing and prevalence of DNA methylation changes at ICRs
have not been systematically investigated in the context of
carcinogenesis.
To test if ICRs are particularly susceptible to epigenetic insult
during carcinogenesis, we first induced lymphoblastic T-cell thy-
mic lymphoma in mice using the KrasG12D mutation under con-
trol of the Cre/LoxP system, and then systematically
characterized DNA methylation changes within imprinted
domains during the progression of the disease from an early stage
(hyperplastic) to a late stage (neoplastic). According to the results,
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DNA methylation changes tend to be restricted to certain regula-
tory elements within imprinted domains and accumulate pro-
gressively among the imprinted domains as the disease advances
toward more infiltrative states. NGS-based bisulfite sequencing
also revealed that certain CpG sites tend to avoid DNA methyla-
tion changes within ICRs that show overall change. In sum, this
study demonstrates that DNA methylation changes are frequent
and dynamic at ICRs during lymphoblastic T-cell thymic lym-
phoma carcinogenesis.
Results
Oncogenic KrasG12D expression results in an infiltrative
T-cell neoplasm
In this study, we challenged a subset of murine cells in vivo
with the KrasG12D mutation and concomitant abrogation of
PEG3 protein seeking to test Peg3 as a tumor suppressor. To
accomplish this, we employed 2 floxed alleles: LSL-KrasG12D and
Peg3floxed (Fig. 1A). First, the LSL-KrasG12D allele features a
floxed set of polyA termination signals inserted between the 1st
and 2nd exons of the Kras locus. The 2nd exon is modified with a
point mutation causing a substitution (glycine to aspartic acid)
for the 12th amino acid of the KRAS protein.13,14 The termina-
tion cassette prevents transcription of the oncogenic KrasG12D
form until it is removed by the activity of cyclic recombinase
(Cre) (Fig. 1A). Second, the Peg3floxed allele features the 6th exon
flanked by 2 loxP sites and thus is excised upon Cre-mediated
recombination.15,16 The PEG3 protein cannot be translated
from the modified ORF of Peg3del6 due to a frame shift and sub-
sequent nonsense mutation. Therefore, when the recombined
allele (Peg3del6) is paternally transmitted, the result is the abro-
gation of PEG3 protein due to the introduced mutation on the
paternal allele and the silencing of the maternal allele by genomic
imprinting (Fig. 1A).
To target these mutations to various tissues/cell types in mice,
we employed an allele that drives expression of Cre by the mouse
mammary tumor virus long terminal repeat promoter (MMTV-
Cre) (Fig. 1A,B).17 This allele has been shown to express Cre in
many of the same cell types where both Kras and Peg3 are
expressed.18 The employed breeding scheme yielded 4 cohorts
(Fig. 1B). The two experimental cohorts were LSL-KrasG12D;
Peg3floxed; MMTV-Cre (KPM) and LSL-KrasG12D; MMTV-Cre
(KM), whereas the 2 negative control cohorts were Peg3floxed;
MMTV-Cre (PM) and MMTV-Cre (M). In cells expressing
MMTV-Cre, the proteins produced for each cohort are as follows:
KPM (KRASG12D and Cre), KM (KRASG12D, PEG3 and Cre),
PM (Cre), and M (PEG3 and Cre). Specific PCR genotyping of
thymic DNA confirmed expected
recombinant products for each
cohort (Fig. 1C).
We obtained 17 litters from the
breeding scheme described above,
which yielded a total of 91 mice
consisting of 12 KPM, 26 KM, 10
PM, and 43 M. In general, there
were no obvious differences in the
gross physical appearance of individ-
uals for each cohort at birth; how-
ever, by one month of age, the coat
for both KPM and KM mice
appeared glossy and thin. This phe-
notype is thought to be the result of
sebaceous gland hyperplasia
(Fig. S1A-B). After one month of
age, both KPM and KM mice
started developing squamous papillo-
mas on their mucus membranes,
both oral and perianal (Fig. S1B).
This is consistent with observations
from previous studies of LSL-
KrasG12D mice.19 The squamous
papillomas caused discomfort for the
animals such that they experienced
difficulties eating and defecating to a
point that the animals of the KPM
and KM cohorts often experienced
significant weight loss (15% of
body weight) by 2 to 4 months of
age. Furthermore, within this time
Figure 1. Targeting oncogenic KrasG12D expression and PEG3 deletion to the mouse thymus. (A)
Upon Cre-mediated recombination: the allele housing the KrasG12D mutation (denoted by *12D) is condi-
tionally expressed by removal of a tandem polyA signal. The critical exon 6 (denoted by yellow colora-
tion) of Peg3 is conditionally deleted. Blue font denotes the allele is paternally inherited and pink font
denotes the allele is maternally inherited. Gray boxes denote exons. Black triangles denote loxP sites.
Filled in lollipops denote a methylated CpG island. Empty lollipops denote an unmethylated CpG island.
(B) Breeding schematic from mating LSL-Kras+/G12D; Peg3+/del6 mice with MMTV-Cre mice to generate
KPM, KM, PM, and M cohorts. (C) Specific PCR analysis of genomic DNA isolated from thymus confirms
recombinant products for each of the targeted alleles.
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period, we observed that mice in both the KPM and KM
cohorts started to experience labored breathing, lethargy, and
signs of pain. Based on these observations, it was deemed neces-
sary to euthanize animals showing signs of distress or significant
weight loss. As a result, the survival of experimental cohorts
(KPM and KM) was significantly reduced (P < 0.001) com-
pared to that of the negative control cohorts (PM and M) such
that the median survival for both experimental cohorts was
approximately 90 d (Fig. 2A). However, there was no significant
difference in survival between the 2 experimental cohorts, KPM
and KM (P = 0.8). These data indicate that the Peg3del6 allele in
KPM mice did not have any additional effect on survival. Both
negative control cohorts did not show any signs of distress, and
remained healthy throughout the duration of the experiment.
Furthermore, both experimental cohorts, KPM and KM,
experienced significant burden due to increased size of liver
(8.0 § 1.1%, P < 0.001 and 11.3 § 1.8, P < 0.001, mean
percent of body weight, respectively), spleen (3.0 §1.5%,
P < 0.001 and 5.1 § 1.5%, P < 0.001, mean percent of body
weight, respectively), and thymus compared to those of negative
control littermates (Fig. 2B,C). Thymus data were not collected
due to the size reduction of this organ as the negative control
mice age. In KPM and KM mice, the pressure imposed by the
oversized liver and spleen most likely resulted in abdominal
pain, and the pressure imposed by the oversized thymus most
likely caused partial lung collapse resulting in shortness of
breath and lethargy. Furthermore, histopathological analyses of
the liver and spleen revealed that these 2 organs had marked
extramedullary hematopoiesis accompanied, in the spleen, by
lymphohistiocytic proliferation in the white pulp (Fig. S1C-F).
In summary, expression of
KrasG12D was primarily respon-
sible for the observed pheno-
types and expression of Peg3del6
did not enhance or contribute
to these phenotypes.
The mice expressing
KrasG12D developed an infiltra-
tive thymic neoplasm. One-
month-old mice had marked
expansion of the cortex by a het-
erogeneous cell population com-
posed of small and large
lymphocytes (Fig. 3A). Older,
3-month-old mice had the thy-
mic architecture completely
effaced by dense sheets of neo-




were CD3 positive and PAX5
negative (Fig. 3B,D). Neoplastic
cells variably infiltrated the adja-
cent adipose tissue, the dorsal
root ganglia, the myocardium at
the base of the heart, the wall of the ventral (sternum) and dorsal
thorax, and the ventral neck musculature (Fig. 3E-H).
The percent of mice developing lymphoblastic T-cell thymic
lymphoma was similar for both experimental cohorts, KPM and
KM, each at 40%. This could be explained by the fact that
anti-PEG3 staining in control and experimental mice was nega-
tive, suggesting that PEG3 is not produced in any cell type within
the thymus (Fig. S2C and E). Because previous studies have sug-
gested that Yin-yang 1 (YY1) may be a suppressor of Peg3 expres-
sion, we also performed anti-YY1 staining; however, similar to
the anti-PEG3 staining, YY1 was not detected in any cell popula-
tion within the thymus (Fig. S2D and F). Thus, these data indi-
cate that the KrasG12D mutation is sufficient to initiate the
development of an infiltrative T-cell neoplasm within the mouse
thymus, and that the Peg3del6 mutation does not enhance the
latency of KrasG12D-induced T-cell lymphoma.
DNA methylation changes at ICRs during progression of
KrasG12D-induced lymphoblastic T-cell thymic lymphoma
For DNA methylation analyses, 15 experimental samples of
the thymus (12 from KM mice and 3 from KPM mice) were
selected: 5 hyperplastic, 5 atypically hyperplastic and 5 neoplastic
lesions, as determined from clinical and pathological observations.
The DNA methylation profiles of the experimental tissue samples
were compared to those of negative control samples from the M
cohort. Combined Bisulfite Restriction Analysis (COBRA) was
used to initially screen for DNA methylation differences.23 This
series of analyses derived the following observations. First, signifi-
cant changes in DNA methylation were more frequently observed
within ICRs than the promoters of Tumor Suppressor Genes
Figure 2. Gross features of mice expressing the KrasG12D mutation. (A) Kaplan-Meier comparative survival
analysis of KM, KPM, PM, and M cohorts. Median survival of KPM and KM mice was significantly less than PM
and M cohorts (P< 0.001, log-rank test, for each pairwise combination). (B) Organ weight profiles of KPM, KM,
PM, and M cohorts. Spleen and liver percent of body weight was significantly increased in KPM and KM cohorts
(P < 0.001, pairwise t-test). (C) Images of hepatomegaly, enlarged thymus, and splenomegaly.
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(TSG). For example, 5 ICRs (Ig, Peg10, Peg3, Nespas, and Grb10)
were significantly hypermethylated, whereas only 2 TSG pro-
moters (Mgmt and Fhit) were significantly hypermethylated, in
the most advanced tumor sample (Fig. 4B). The most affected
was the Ig-ICR, showing significant hypermethylation in 73% of
the samples. In contrast, hypermethylation within promoters of
the most affected TSGs, Mgmt and Fhit, was only detected in
20% of the samples. Collectively, 60% of DNA from lymphoblas-
tic T-cell thymic lymphoma displayed aberrant DNA methylation
in 2 or more ICRs, whereas only 6% of these DNA displayed
aberrant DNAmethylation in 2 or more TSG promoters (Fig. 4).
Second, the majority of changes
observed in ICRs were hyperme-
thylation. Only the Peg10-ICR
displayed either hyper- or hypo-
methylation among 60% of the
samples. In this case, the fre-
quency of hypermethylation was
0.13, whereas the frequency of
hypomethylation was 0.47. Inter-
estingly, hypomethylation of the
Peg10-ICR was the only detectable
change in 3 out of the 5 hyper-
plastic samples (Fig. 4). Thus,
these data indicate that aberrant
DNA methylation in the Peg10-
ICR may be one of the first
detectable changes in lymphoblas-
tic T-cell thymic lymphoma.
Third, several tumor samples
displayed both hyper- and hypo-
methylation in the tested ICRs.
In sample 6, the mean percent
methylation of the Peg10-ICR
reduced to 29 § 4% (P = 0.006),
yet mean percent methylation drastically increased to 84 § 2%
(P < 0.001) in the Ig-ICR and 87 § 6% (P < 0.001) in the
Peg3-ICR (Fig. 5; Fig. S3). These coexisting hyper- and hypo-
methylation data indicate that changes within ICRs are not the
result of global changes to the methylome toward hypermethyla-
tion at CpG islands; rather, these changes are the result of dis-
crete events. In summary, these data demonstrate that aberrant
DNA methylation within ICRs is precocious and dynamic in
T-cell lymphoma. The complete set of mean percent methyla-
tion graphs for each ICR and DMR with significant changes is
available (Fig. 5; Fig. S3).
DNA methylation changes





We also surveyed DNA
methylation in other regulatory
regions within imprinted
domains. First, we measured
DNA methylation changes at
distal enhancers, since these
elements are known to be vul-
nerable during carcinogene-
sis.24 For this test, we
measured the DNA methyla-
tion levels of a putative
enhancer found within the
Figure 3. Histological thymic alterations in KM mice. (A) The cortex is expanded by a heterogeneous
(hyperplastic) lymphoid cell population, with retention of the normal thymic architecture in a 1-month-old
KM mouse. (B) The architecture of the hyperplastic thymus in a 1-month-old KM mouse is maintained, with
the majority of CD3 immunopositive cells in the cortex. (C) The normal architecture of the thymus is
completely effaced by a lymphoid round cell neoplasm in a 2.5-month-old KM mouse. (D) Neoplastic lym-
phoid cells effacing the thymus in a 2.5-month-old KM mouse are diffusely CD3 immunopositive, consistent
with T-cell origin of the neoplasm. (E-G) H&E staining of nearby tissues. (E) Neoplastic cells invade adjacent
adipose tissue. (F) Neoplastic cells encircling ganglia. (H) Neoplastic cells invade the myocardium at the base
of the heart (G) Neoplastic cells invade the musculature of the sternum. All insets show to neoplastic cells at
400X.
Figure 4. Signature of aberrant DNA methylation in KrasG12D-induced lymphoblastic thymic T-cell lym-
phoma. Heat map summary of the quantified COBRA data for all ICRs tested in 15 thymic samples. Based on
P values from pairwise T-test, each locus tested in the thymic samples was determined to be hypermethylated
(red), hypomethylated (green), or not changed (gray). The gradation of yellow in the sample # column depicts
progression of the disease state from hyperplastic (white) to atypically hyperplastic to neoplastic (yellow).
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Peg3 domain, termed ECR18.25 According to the results, the
Peg3-ICR displayed significant hypermethylation in 6 out of 15
samples (#2, 4, 6, 8, 10, and 14), and Peg3-ECR18 displayed sig-
nificant hypermethylation in 7 out of 15 samples (#2, 6, 7, 8, 9,
12 and 14). Interestingly, sample #7 displayed similar methyla-
tion levels at both the Peg3-ICR (62 § 9%) and Peg3-ECR18
(55 § 12%). However, the change in methylation was only sig-
nificant for Peg3-ECR18 due to the low level of methylation at
the enhancer region and 50% methylation at the ICR in normal
tissue. Furthermore, the Peg3-ECR18 displayed significant
hypermethylation in samples #9 and #12 while the ICR
remained unaffected suggesting
that the enhancer region acquired
DNA methylation changes before
the ICR.
Second, we also surveyed the
DNA methylation levels of the dif-
ferentially methylated region
(DMR) and promoter for the 2
imprinted genes, Gnas and Dlk1
(Fig. 6). Interestingly, neither the
DMR nor the promoter for either
gene displayed any changes in
DNA methylation. However, the
ICRs for both genes frequently expe-
rienced significant changes. The ICR
for the Gnas domain, Nespas-ICR,
was hypermethylated in 3 out of 15
samples and the ICR for the Dlk1/
Gtl2 domain, Ig-ICR, was hyperme-
thylated in 11 out of 15 samples
(Fig. 6). These data demonstrate that
ICRs are more sensitive to DNA
methylation changes than DMRs or promoters. Taken together,
these results demonstrate that ICRs and enhancer elements are both
more sensitive to DNA methylation changes than DMRs or pro-
moters, and that changes in methylation within enhancer elements
may be more readily detectable.
Bisulfite sequencing revealed hypermethylation-resistant
CpG sites within ICRs
We also performed NGS-based bisulfite sequencing for a subset of
the PCR products to get a more holistic view of DNA methylation
changes. PCR products were selected from 7 experimental samples (4
KM and 3 KPM) and one control
sample (N). Results from the Peg3-
ICR are displayed as a representative
set (Fig. 7). Inspection of the sequenc-
ing results allowed for the following
observations. First, sequencing results
weremostly consistent with the results
generated by COBRA, confirming
that there was a correlation between
DNA methylation levels and the
degree of tumor progression in the
tested samples (Figs. 4 and 7). In the
hyperplastic sample (#13), the DNA
methylation pattern was consistent
with the pattern in the control sample
(N), where approximately one half of
the heatmapwas red (denotingmeth-
ylated CpG sites) and the other half
was blue (denoting unmethylated
CpG sites). This is the typical pattern
generated by normal levels of DNA
methylation due to ICRs being meth-
ylated on one allele and unmethylated
Figure 5. Distal enhancer regions may prove to be effective biomarkers. A-B: Aberrant DNA methylation
comparison of the Peg3-ICR and the Peg3-ECR18. A: COBRA of the Peg3-ICR. B: COBRA of the Peg3-ECR18.
Unmethylated DNA is denoted with a U. Methylated DNA is denoted with a M. Stars represent significant
increases in DNA methylation compared to normal DNA (denoted by the letter N). Experimental samples are
numbered 1–15. Red represents hypermethylation, gray represents no change, and blue represents normal/
control levels.
Figure 6. Aberrant DNA methylation is targeted to ICRs within imprinted domains. Images generated
from COBRA analysis of 3 regulatory regions within the Gnas and Dlk1/Gtl2 domains. For each domain, the
ICR, a nearby DMR and a nearby promoter were measured. Unmethylated DNA is denoted with a U, while
methylated DNA is denoted with an M. The enzymes used to digest each amplicon are presented under the
name of each PCR product.
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on the other. However, the normal pattern was no longer present in
neoplastic samples such as # 2, representing the most advanced tumor.
This sample was hypermethylated to such an extent that meanmethyl-
ation was nearly 84%,which rendered the portion of the heatmap rep-
resenting the unmethylated allele virtually non existent (Fig. 7).
Second, certain CpG sites were resistant to DNA methylation
change. Within the amplicon for the Peg3-ICR, this trend was
evident by a subset of CpG sites maintaining the normal half red
and half blue pattern even though other CpG sites were methyl-
ated in 90% or more of sequencing reads. The CpG sites particu-
larly maintaining the normal pattern were # 3, 4, 7, 12, and 13
(Fig. 7). Inspection of the sequences surrounding these resistant
CpGs indicated that these sites are part of potential regulatory
sequences. CpG Nos. Three,4 and 7 are part of the GC-box
motif, 50 – GGGCGG – 30, and CpGs # 12 and 13 are part of
the palindrome, 50 – CGATCG – 30. Two of the CpGs # 4 and
7 are within a putative conserved sequence element (CSE1) that
is known to attract an unknown repressive protein complex to
the Peg3-ICR.26,27 Interestingly, another conserved GC-box
motif happens to be localized just outside CSE1, yet this is the
motif housing the most resistant CpG site # 3 based on its meth-
ylation status most evident in the heat map for sample # 2
(Fig. 7). Overall, this series of analyses demonstrated that DNA
methylation changes expand during tumor progression and that
certain CpG sites might be protected from DNA methylation
changes potentially due to the binding of unknown transcription
factors.
Discussion
Analyses of many human cancers suggest that the methylation
status of genomic imprinting is challenged during carcinogenesis
and that loss of imprinting (LOI) contributes to neoplastic trans-
formations.12 However, the con-
text (i.e., the causative genomic
mutation) in which DNA methyl-
ation changes occur within
imprinted domains can rarely be
determined. Furthermore, it may
not be possible to determine which
mutation, the genomic or the epi-
genomic, is established first in spo-
radic human tumors. Further
complicating matters, DNA meth-
ylation signatures within
imprinted domains vary from one
tumor type to the next.8 There-
fore, it is necessary to survey DNA
methylation of imprinted domains
in various tumor types in which
the causative genomic mutation is
known. Here, we induced lym-
phoblastic T-cell thymic lym-
phoma in mice using the KrasG12D
oncogene and systematically sur-
veyed for aberrant DNA methyla-
tion within imprinted domains.
With this study, we show that
DNA methylation in imprinted
domains is frequently challenged
in T-cells expressing KrasG12D
(Fig. 4) and that DNA methyla-
tion changes do not occur equally
within an imprinted domain.
Rather, these changes occur most
frequently at ICRs (or “control
DMRs”) and enhancers (Figs. 5,
6) of imprinted domains. Further-
more, we found that certain evolu-
tionarily conserved sequence
elements that attract DNA bind-
ing proteins are resistant to DNA
Figure 7. Bisulfite NGS reveals not all CpG are equally vulnerable to DNA methylation changes. Heat
maps generated by BiQ analyzer HT showing DNA methylation at each CpG (Nos. One–16) within bisulfite
PCR products. Results from the Peg3-ICR are shown as a representative set. Each column represents a CpG
within the bisulfite PCR product and each row represents a sequencing read. The positions of the restriction
sites utilized in COBRA are indicated below the heat map of the control sample (N) with triangles (black for
TaqaI and purple for HphI). Mean methylation (%) and number of reads are presented above each map.
Below the heat maps is a UCSC genome browser view of putative CSEl containing CpGs # 4–7. Sequences
are highlighted based on matching the consensus motif of the SP1 transcription factor. An expansion of
CSE1 is proposed based on the most hypermethylation resistant CpG, # 3, being contained in a highly con-
served region that matched very well with the SP1 binding motif and was not included in putative CSE1.
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methylation changes (Fig. 7). Overall, the ICRs of the Peg10,
Dlk1/Gtl2, and Peg3 domains experienced the most notable
DNA methylation changes in T-cell lymphoma (Fig. 4).
Aberrant DNA methylation within the Peg10 and Dlk1/Gtl2
domains has also been reported in human B-cell leukemias and
malignancies.8 The consistency of these 2 domains experiencing
changes in both B-cell and T-cell neoplasms has several implica-
tions. First, detecting DNA methylation changes cannot be used
to determine the cell type responsible for lymphocytic tumors.
However, detection of aberrant DNA methylation within
imprinted domains may provide insight into the severity of a dis-
ease. For instance, while the only detectable changes in hyper-
plastic tumors occurred in the Peg10 and Dlk1/Gtl2 domains,
changes were frequently detected within several other domains
such as Peg3 in neoplastic tumors (Fig. 4). Thus, detection of
aberrant DNA methylation in imprinted domains other than
Peg10 and Dlk1/Gtl2 suggests lymphocytes have already under-
gone neoplastic transformation. Second, because the Peg10 and
Dlk1/Gtl2 domains experience detectable changes in hyperplastic
tumors, changes in these domains may contribute to neoplastic
transformation. If this does prove to be the case, then specific
therapeutic modalities may be designed to restore normal DNA
methylation settings within these domains. Lastly, neither the
causative genomic mutation nor the specific cell type may be
directly responsible for changes in DNA methylation. Rather,
distinct DNA methylation signatures are likely established based
on whether or not the epimutation provides a selective advantage
for a given tumor cell.
ICRs contain a variety of DNA sequence elements that have
been linked to hyper- and hypo-methylation trends, which are
notorious for increasing cancer heterogeneity.28,29 These
sequence elements include tandem repeats, CpG islands, and
ncRNA promoters, all of which often co-exist within an ICR.1
For instance, while CpG islands tend to attract hypermethyla-
tion, tandem repeat sequences frequently become hypomethy-
lated.28 Thus, any given ICR has the potential to either gain or
lose methylation. This phenomenon is showcased quite nicely by
our analysis of the Peg10-ICR. The Peg10-ICR was hypomethy-
lated in 7 samples and hypermethylated in 2 samples among the
9 T-cell neoplasms that displayed DNA methylation changes
within this region. PEG10 has been derived from retrotranspo-
sons, which may account for the frequent hypomethylation. At
the same time, the ICR of the Peg10 domain contains a CpG
island, which may account for the hypermethylation. Therefore,
the unusual clustering of various sequence elements within ICRs
may be what first attracts DNA methylation changes. Most often,
the changes that occur at ICRs will not contribute to disease pro-
gression. However, when certain epimutations at ICRs do con-
tribute to the carcinogenesis of a particular tumor cell type, they
can be selected for and propagated by rapidly dividing tumor
cells until the epimutation is fixed in what now can be considered
an evolved population of tumor cells.
DNA methylation changes are primarily restricted to ICRs
within an imprinted domain. Invasive breast cancer fre-
quently displays aberrant DNA methylation within several
imprinted domains and loss of imprinting does not
necessarily accompany DNA methylation changes.30 How-
ever, it is still unclear whether the observed methylation
changes could be the result of shifting DNA methylation
boundaries or specific DNA methylation changes contained
within imprinted domains.30 According to the results of our
analyses of the Dlk1/Gtl2 and Gnas domains, the ICRs of
these domains frequently experienced aberrant DNA methyla-
tion, but regions outside of the ICRs (i.e., nearby DMRs and
promoter regions) were not affected (Fig. 5). Therefore, we
believe that DNA methylation changes are not the result of
shifting DNA methylation pattern. Rather, aberrant DNA
methylation is confined to certain regions of imprinted
domains, particularly ICRs.
ICRs are unusually sensitive to DNA methylation changes
during carcinogenesis, but there may be other regions of the
genome that are just as sensitive. While surveying the Peg3
domain, we observed that an evolutionarily conserved region
(ECR18), a putative enhancer for the Peg3 domain, was hyper-
methylated at a similar frequency even though it is 200 kb
upstream from the Peg3-ICR (Fig. 6). Although this observation
implies that enhancer regions may also be unusually sensitive to
DNA methylation changes during carcinogenesis, further investi-
gations into several other enhancer regions are needed to confirm
this preliminary observation. However, this observation is consis-
tent with recent reports that demonstrated DNA methylation of
transcriptional enhancers is associated with cancer predisposi-
tion.31 It will certainly be interesting to further investigate how
changes in DNA methylation at enhancer regions can impact
nearby gene expression profiles within tumor cells and how such
changes contribute to carcinogenesis. If enhancer regions do
prove to be particularly vulnerable to DNA methylation changes
in tumor cells, they could make excellent biomarkers given their
ubiquitous distribution in the genome.
Bisulfite sequencing analyses revealed that DNA methylation
changes are not only variable among ICRs, but also variable
within a single ICR. For instance, while the sequencing results
were consistent with the COBRA results, they also revealed an
unexpected pattern in tumor cells. Certain CpG sites remained
unaffected even though neighboring CpG sites experienced
extensive hypermethylation. Upon close inspection of the imme-
diate sequences surrounding the resistant CpG sites, we noticed
that these sites are within the GC-box motif, 50 - GGGCGG - 30
(Fig. 7). There are 2 possibilities that may be responsible for this
trend. First, certain CpG sites remain unaffected due to the bind-
ing of unknown transcription factors, which may have a role in
genomic imprinting or transcription of imprinted genes within
the region. Second, the unaffected CpGs may simply be within
DNA segments that are less accessible to the DNA methyltrans-
ferase machinery due to nucleosome occupancy. Since the only
observed resistant sites were part of well-known consensus
sequences, we favor the first scenario that these CpG are shielded
from DNA methylation because of being bound by proteins.
However, we plan to further investigate this hypothesis in the
near future.
Previously, we have identified a conserved sequence element
(CSE1) within the Peg3 domain. According to the results, an
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unknown protein complex binds to CSE1, and this complex is
predicted to be a strong repressor for the expression of Peg3.26,27
Upon close inspection of the CpG sites (Nos. Four–7) of the
Peg3-ICR amplicon, which are localized within putative CSE1,
we realized CpGs sites Nos. Four and 7 are part of a well-known
motif, the GC-box. Oddly, there was a CpG site (# 3) immedi-
ately outside the 42-bp putative CSE1 sequence that is also part
of a GC-box motif. Interestingly, this CpG site was most resis-
tant to DNA methylation and is highly conserved among placen-
tal mammals (Fig. 7). Furthermore, when we included the
slightly degenerate sequences surrounding the core sequence of
the GC box, we noticed a surprising trend: these evolutionarily
conserved sequences fit very well with the consensus sequence, 50
- (G/T)GGGCGG(G/A)(G/A)(C/T) - 30, known to be bound
by the SP1 transcription factor32 (Fig. 7). The CpG sites within
this consensus sequence resisting DNA methylation change is
consistent with a previous study which reported that the SP1 pro-
tein protects CpG islands from de novo DNA methylation.33
Although this observation suggests SP1 as a possible candidate
protein binding to this region, further testing is required to sup-
port the hypothesis that SP1 binds to CSE1 and subsequently
regulates Peg3 expression. Nonetheless, the current results suggest
that the previously defined region of CSE1 may need expansion
to include the outlying GC-box as a conserved cis-regulatory
module (Fig. 7).
To our knowledge, this is the first study to challenge murine
cells with a potent oncogenic mutation and then systematically
survey imprinted domains for aberrant DNA methylation. The
results from the DNA methylation analyses of this study demon-
strate that the DNA methylation status of ICRs is unstable and
that aberrant DNA methylation accumulates among several ICRs
during carcinogenesis of lymphoblastic T-cell thymic lymphoma.
Whether the observed DNA methylation changes within ICRs
directly contribute to the development of a tumor cell population
or are merely the result of the accumulation of changes over time
in the tumor cell methylome is still unknown and requires fur-
ther investigation. However, considering that the function of
many imprinted gene products is frequently associated with phys-
iological cellular processes such cell growth and death and how
sensitive imprinted genes dosage is to these physiological pro-
cesses, it is likely that changes within ICRs for a subset of
imprinted genes such as Peg10, Dlk1, Gnas, and Peg3 could alter
gene expression and tip the scales such that a tumor cell popula-
tion could gain a competitive edge and proliferate with fewer
checks and boundaries.
Materials and Methods
Mouse strains. Three mouse stains were maintained for the
duration of the experiment. Two publically available mouse
strains, B6.129-Krastm4Tyj/Nci (LSL-KrasG12D) and STOCK Tg
(MMTV-Cre)4Mam/J (MMTV-Cre), were purchased from Jack-
son Laboratories.13,14,15 The third strain, Peg3floxed, was gener-
ated in the lab.16,17 The order of breeding was carried out as
follows: first, the Peg3floxed allele was bred with the LSL-KrasG12D
model to generate double heterozygous mice. Next, male double
heterozygous mice for Peg3floxed and LSL-KrasG12D were bred
with female homozygous MMTV-Cre mice. This breeding
scheme yielded progeny with 4 different genotypes: KPM, KM,
PM, and M (Fig. 1B). All experiments were performed in accor-
dance with National Institutes of Health guidelines for care and
use of animals, and also approved by the Louisiana State Univer-
sity Institutional Animal Care and Use Committee (IACUC),
protocol #13–061.
Genotyping. All litters were weaned 21 d post partum and lit-
termates were separated by gender based on comparing the rela-
tive distance of the genitalia from the perianal membrane. No
more than 5 littermates were housed in a single cage. Littermates
were identified through varying positions of a hole punch on the
left ear. Genomic DNA from a right ear clip was used for PCR
genotyping. Ear clips were lysed overnight at 60C in a solution
with tail lysis buffer (100 mM Tris-HCl pH 8.1, 5 mM EDTA,
200 mM NaCl, 0.2% SDS) supplemented with Proteinase K
(NEB, Cat. # P8107S). Lysates were diluted at 1:60 with nano-
pure water. Two microliter of diluted lysate was directly added to
Maxime PCR Premix tubes (intron, Cat. # 25167) followed by
1 ml of primer at the concentration of 10 pM and nanopure
water to bring the reaction to 20 ml. The following specific
primer sets were used for each of the following mouse strains:
Peg3FlpKo/Del6: Peg3 5arm 50 – CCCTCAGCAGAGCTGTTTC-
CTGCC - 30 and Peg3 LoxR 50 – TGAACTGATGGCGAGCT-
CAGACC – 30 and Peg3 rev 50 –ACCCCATTCTCAT-
CAGCTCCAGAG – 30; MMTV-Cre: MMTV-Cre F 50
–CTGATCTGAGCTCTGAGTG – 30 and MMTV-Cre R 50
–CATCACTCGTTGCATCGACC – 30; LSL-KrasG12D: Kras
F1 50 – GTCTTTCCCCAGCACAGTGC – 30 and Kras Fcass
50 –AGCTAGCCACCATGGCTTGAGTAAGTCTGCA - 30;
L-KrasG12D: Kras F1 50 –GTCTTTCC-CCAGCACAGTGC –
30 and Kras R1 50 - CTCTTGCCT-ACGCCAC CAGCTC –
30. Genotyping PCR conditions for 33 cycles were as follows:
denaturation at 95C for 30 seconds, annealing at 60C for 30
seconds, and extension at 72C for 1 minute.
Histology and Immunohistochemistry. Mice were sacrificed by
CO2 asphyxiation in accordance with the rules and regulations
set forth by the IACUC either when showing signs of distress
or when reaching 15% weight loss (weight measurements were
taken every 3 d for mice expressing the KrasG12D mutation). A
full necropsy was performed on all mice. Tissues were fixed in
10% neutral buffered formalin (Thermo Scientific, Cat. #
5725) for at least 48 hours, and then transferred to 70% etha-
nol for storage. Tissues were trimmed and embedded in paraf-
fin, sectioned, and stained with hematoxylin and eosin
(H&E). Sections were evaluated by a board-certified veterinary
pathologist (IML). Samples of oral, anal and foot pad masses
and any other tissue that appeared grossly abnormal were also
placed in lysis buffer containing Proteinase K for subsequent
DNA extraction and analyses. The standard method was used
for immunohistochemistry. Briefly, paraffin blocks were sec-
tioned at 5 mm and deparaffinized (3 xylene changes, 5 min
each; 3 washes with 100% ethanol, 4 min each; one wash
with 95% EtOH, 4 min; one dH2O rinse; and one buffer
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rinse). Slides were soaked in 3% H2O2/dH2O for 10 min to
quench endogenous peroxidase activity, and were incubated
with normal goat blocking serum for 30 min. Antigen-retrieval
was performed with a Biocare Decloaker for 20 min in
DAKO citrate buffer pH 6. Primary antibodies were diluted
with the DAKO antibody diluent, and were applied at room
temperature for 30 minutes for anti-CD3 (Santa Cruz Bio-
technology, Cat. # sc-1127), anti-PAX5 (Santa Cruz Biotech-
nology, Cat. # sc-1974) and anti-Peg3,17 and one hour for
anti-YY1 (Santa Cruz Biotechnology, Cat. # sc-7341). The fol-
lowing primary antibody dilutions were used: anti-CD3
(1:350), anti-PAX5 (1:300), anti-Peg3 (1:50), and anti-YY1
(1:100). Biotinylated anti-goat in rabbit and biotinylated anti-
rabbit in goat secondary antibodies were diluted with the
DAKO antibody diluent and applied to the slides. Slides were
counterstained with Hematoxylin. Staining was performed on
a DAKO Autostainer Link 48.
DNA methylation analyses: COmbined Bisulfite Restriction
Analysis (COBRA) and Next Generation Sequencing (NGS). Geno-
mic DNA was purified from mediastinal tissue samples by spin
column recovery (Genomic DNA clean and concentrator-25,
Zymo Research, Cat. # D4065). Purified genomic DNA
(500 ng) from each mediastinal lesion was bisulfite-converted
using a commercial kit (EZ DNA methylation kit, Zymo
Research, Cat. # D5002). The converted DNA was used for
PCR amplification. The detailed information regarding the
sequences and genomic position for each oligonucleotide set has
been presented as Table S1. The amplified PCR products from
bisulfite-converted DNA were digested with restriction enzymes,
separated on a 2% agarose gel, and the relative amount of each
digested DNA fragment was measured based on its band density
as described below. QuantityOne software was used to export gel
electrophoresis images as lossless tiff files (Gel Doc system, Bio-
Rad). Tiff files were then processed as 8-bit grayscale using
ImageJ software34 in the following manner: 1) data was inverted;
2) background was subtracted using default setting; 3) bright-
ness/contrast was adjusted by selecting the auto adjust command
one time; 4) bands in each lane were selected individually using
the rectangular tool; 5) density plots were then generated for
each rectangular selection; 6) each density peak was gated at the
base of the peak at a location higher then background signals
using the line drawing tool; and 7) the area under each peak was
automatically generated by the software using the wand tool.
Area results were exported into an Excel spreadsheet where all
subsequent analyses were performed. DNA Methylation values
(%) were calculated using the following formula: 100*[(area of
peak from digested DNA/s)/(area of peak from digested band/s +
area of peak from undigested DNA)]. ANOVA (single factor)
statistical analysis was performed on the percent methylation
results for each locus screened. If the P value from the ANOVA
analysis was less than or equal to 0.05, then subsequent pair wise
t-test (2 sample assuming equal variance) was performed compar-
ing each tumor sample to normal tissue for each locus. Three
independent trials starting from bisulfite conversion to restriction
digestion were repeated to derive the average DNA methylation
levels of each locus within 95% confidence intervals.
Sequencing of the individual bisulfite PCR products was per-
formed using a NGS platform (PGM2, Ion Torrent, Life Tech-
nologies). Briefly, bisulfite PCR products for each locus from
each trial were pooled for 7 representative thymic lesions, and for
one control thymus. End repair was performed using a commer-
cially available module (NEBNext End Repair Module, Cat. #
E6050S). End-repaired bisulfite PCR products were then visual-
ized by electrophoresis, size-selected, and extracted using a com-
mercially available kit (Gel DNA recovery kit, Zymo Research,
Cat. # D4001). Barcoded adapters were ligated to each thymic
lesion’s pooled bisulfite PCR products by the activity of 2
enzymes in concert (Bst 2.0 WarmStart, NEB, Cat. # M0538S
and T4 DNA ligase, NEB, M0202S). The adapter ligation reac-
tions were visualized with gel electrophoresis, and the products
were extracted using the Zymo kit referenced above. PCR with
primers specific for the adapters was used to enrich for the PCR
products that had the proper adapter orientation. The enriched
PCR products were then submitted to the genomics core facility
at Louisiana State University (LSU) for sequencing. The raw
sequence reads were processed in the following manner. Briefly,
Sequence reads smaller than 100 bp in length were discarded.
The remaining sequences were first sorted by bar code for each
thymic lesion, and then sorted by the primer sequences specific
for each PCR product such that forward and reverse reads were
sorted into the same directory. The BiQ Analyzer HT tool was
used to further process the sorted sequences such that reads with
greater than or equal to 80% bisulfite conversion and 50%
sequence identity were analyzed to calculate DNA methylation
levels for each locus.35 The bioinformatics pipeline used for this
process is available upon request.
Survival analyses and organ weight profiles. For each animal, date
of birth and date of necropsy were recorded and compared by
Kaplan Meyer survival analyses of the 4 cohorts using GraphPad
Prism Version 4.0 software. However, for ease of formatting,
Microsoft Excel was used to generate the survival curve graph.
Upon necropsy, each animal’s body, liver, spleen and right kidney
weights were measured using a thermo scientific digital scale with
0.001 g accuracy. Data was imported into Microsoft Excel and was
processed in the following manner. Each organ’s percent of body
weight was calculated mean % weight = 100*(weight of organ/total
body weight). For each cohort, mean percent weight of kidney,
spleen and liver was calculated and plotted with 95% confidence
intervals. ANOVA (single factor) was used to compare the percent
weights of each organ type among the 4 cohorts. If the P-value from
the ANOVA analysis was less than or equal to 0.05, then subse-
quent pairwise t-tests (2 sample assuming equal variance) were per-
formed to compare each cohort to one another for each organ type.
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